VISTA-GROUP
10.4.2018 18:52:03 CEST | Business Wire | Press release
Vista Entertainment Solutions (Vista Cinema), the leading provider of cinema management software for the global cinema exhibition market, has completed the rollout for its first customer in Italy, The Space Cinema, which operates 36 cinemas with 362 screens. The Space Cinema is part of Vue International.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180410006322/en/
Vista Group Chief Executive Kimbal Riley describes the rollout as a fantastic achievement. “This was a challenging regulatory process in a new territory for Vista and builds on the strong relationship we have with Vue International. It’s a great testament to our excellent local partners that we’ve been able to complete this rollout.”
Managing Director, Europe, Middle East and Africa at Vista Entertainment Solutions, Mischa Kay says: “Together with the fantastic team at The Space Cinema, we have successfully rolled out a broad selection of the Vista Cinema software suite across the Italian circuit. Italy is a top 20 cinema-going market and represents a significant opportunity not only for Vista Cinema, but for the Vista Group as a whole, to provide business benefits to the Italian industry.”
“Vue International continues to implement best practices across its group of circuits in Europe,” says Roland Jones, Executive Director, Technical Services, Vue International. “We are pleased to have extended our relationship with Vista, with whom we have worked extensively in the UK for many years. By introducing Vista’s state-of-the-art, integrated operating system to cinemas such as The Space, we maximize a host of benefits that only the leading global cinema system can deliver.”
The Managing Director of The Space Cinema, Toby Bradon, has also welcomed the completion of the rollout: “On behalf of The Space Cinema, we are very pleased to be the first Italian circuit working with Vista. Following a rapid and successful implementation we look forward to maximising the benefits of Vista’s modern, class-leading cinema operating system. Working in conjunction with our colleagues at Vue International, The Space Cinema continues to invest in its customer experience supporting our mission to be the first choice in cinema entertainment in Italy.”
About The Space Cinema:
The Space Cinema is a leading cinema operator in Italy with 36 multiplex cinemas and 362 screens. Space owns five out of the top ten highest grossing cinemas in Italy including the No.1 grossing cinema in the Italian market - Parco de Medici. The business is a leader in a fragmented cinema market. At the end of 2014, The Space Cinema was acquired by Vue Entertainment International.
About Vue International
Vue International is one of the world's leading cinema operators,
managing the most respected brands in major European markets and Taiwan,
spanning ten countries, 212 sites and 1,902 screens. The group has
leading positions in the United Kingdom, Ireland, Germany, Denmark,
Netherlands, Italy, Poland, Latvia, Lithuania and Taiwan. From its
inception in May 2003 Vue International has grown organically and
through strategic acquisition to deliver a premium out-of-home
entertainment experience by combining the best content, with the best
technology in the best environment.
Website: www.myvue.com/about-us
About Vista Group International:
Vista Group International (Vista Group) is a public company, listed on
both the New Zealand and Australian stock exchanges (NZX & ASX: VGL).
The Group provides software and additional technology solutions across
the global film industry. Cinema management software is provided by
Vista Entertainment Solutions (Vista Cinema), the core business of the
Group. Movio (authority in moviegoer data analytics), Veezi (cloud-based
SaaS software for the Independent Cinema Market), movieXchange
(connecting the movie industry to simplify the promotion and sale of
movie tickets), Maccs (film distribution software), Numero (box office
reporting software for film distributors and cinemas), Cinema
Intelligence (business intelligence solutions), Powster (creative studio
and marketing platform for movie studios) and Flicks (moviegoer ‘go to’
portal for movie information) provide an innovative range of
complementary products across additional film industry sectors, from
production and distribution, to cinema exhibition through to the
moviegoer experience. Vista Group has offices located in New Zealand
(Auckland HQ), Sydney, Los Angeles, London, Shanghai, Beijing, Mexico
City, South Africa, the Netherlands and Romania.
Website: www.vistagroup.co
LinkedIn:
www.linkedin.com/company/vista-group-limited
View source version on businesswire.com: https://www.businesswire.com/news/home/20180410006322/en/
Contact:
Media Contacts:
For Vista Group International/NZ & EUROPE
Christine
Fenby
+64 21 727 006
christine.fenby@vista.co
or
For
Vista Group International/USA
Maggie Begley/MBC
+1 310 390
0101
maggie@mbcprinc.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom